Protalix BioTherapeutics (PLX) Other Accumulated Expenses (2023 - 2026)

Protalix BioTherapeutics' Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $973000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 224.33% year-over-year to $973000.0; the TTM figure through Mar 2026 stood at $973000.0 (up 224.33% YoY), while the FY2025 annual figure was $799000.0, down 26.02% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $973000.0, up from $799000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $1.1 million in Q4 2024, with the low at $300000.0 in Q1 2025.
• The 4-year median for Other Accumulated Expenses is $763000.0 (2025), against an average of $730000.0.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses decreased 26.02% in 2025, then surged 224.33% in 2026.
• Protalix BioTherapeutics' Other Accumulated Expenses stood at $637000.0 in 2023, then soared by 69.54% to $1.1 million in 2024, then fell by 26.02% to $799000.0 in 2025, then climbed by 21.78% to $973000.0 in 2026.
• Business Quant data shows PLX's Other Accumulated Expenses at $973000.0 in Q1 2026, $799000.0 in Q4 2025, and $558000.0 in Q3 2025.